ClinicalTrials.gg
RecruitingNCT07607080META-RESPIREUpdated Jun 8, 2026

Predicting High-Flow Nasal Cannula Failure in Acute Hypoxemic Respiratory Failure Using Metabolomics and Clinical Data

An observational study in Acute Hypoxemic Respiratory Failure, sponsored by Hospital del Mar Research Institute (IMIM). Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Hospital del Mar Research Institute (IMIM) · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.

Planned enrollment
14th of 31
300 · median 298
Started
2026
with 4 others
Observational
31 of 69
5 open now
Primary completion
2029-05
later than 14 of 14 live
Registered
65th of 69
by date
Lead sponsor
3 of 69
Hospital del Mar Research Institute (IMIM)

Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 14th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2026, is one of 31 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 65th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Respiratory Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are:

Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes?

Participants will:

Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.

Read the detailed description

This observational study aims to evaluate whether metabolomic signatures combined with routinely collected clinical and physiological data can improve the prediction of high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF). HFNC is widely used as first-line non-invasive respiratory support in AHRF; however, delayed recognition of treatment failure may lead to worse clinical outcomes, including delayed intubation and increased morbidity and mortality.

The study will prospectively enroll adult patients with AHRF treated with HFNC. Clinical variables, respiratory parameters, laboratory results, and patient outcomes will be collected during routine clinical care. Blood samples will also be obtained for metabolomic analysis to identify molecular profiles associated with HFNC success or failure.

The primary objective is to identify metabolomic and clinical predictors associated with HFNC failure and escalation of respiratory support. Secondary objectives include evaluating the association between metabolomic patterns and relevant clinical outcomes such as endotracheal intubation, duration of respiratory support, intensive care unit (ICU) length of stay, and mortality. The study also aims to develop predictive models integrating biological and clinical data to support personalized respiratory management strategies in AHRF.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure

Keywords

  • Acute Hypoxemic Respiratory Failure (AHRF)
  • High-Flow Nasal Cannula (HFNC)
  • Metabolomics
  • Respiratory Failure Prediction
  • Noninvasive Respiratory Support
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients admitted to intensive care units (ICUs) with acute hypoxemic respiratory failure (AHRF) requiring treatment with high-flow nasal cannula (HFNC) as part of routine clinical care. Participants will be prospectively recruited from tertiary-care hospitals in Catalonia, Spain, including: Hospital del Mar, Hospital de Bellvitge, Hospital Parc Taulí, Hospital Joan XXIII

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old).
  • Admission to the intensive care unit (ICU) with acute hypoxemic respiratory failure (AHRF).
  • Treatment with high-flow nasal cannula (HFNC) as the initial respiratory support strategy.
  • Inclusion within the first 24 hours after HFNC initiation.
  • Provision of by the patient or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years.
  • Active do-not-resuscitate (DNR) orders or limitation of therapeutic effort.
  • Refusal or inability to provide .
  • Previous invasive mechanical ventilation before study inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Adult Patients With Acute Hypoxemic Respiratory Failure Treated With HFNC

    Adult patients with acute hypoxemic respiratory failure receiving high-flow nasal cannula (HFNC) as part of routine clinical care. Clinical, physiological, and metabolomic data will be collected to evaluate predictors of HFNC failure and respiratory support escalation.

06

What researchers measure

Primary outcomes

  1. HFNC Failure

    Failure of high-flow nasal cannula (HFNC), defined as the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF).

    Time frame: Within the first 28 days after HFNC initiation.

Secondary outcomes

  1. Predictive Performance of the Metabolomic-Clinical Model

    Comparison of the predictive accuracy of the metabolomic-clinical model versus the ROX index for predicting HFNC failure.

    Time frame: Baseline and within the first 24 hours after HFNC initiation.

Other outcomes

  1. ICU Mortality

    All-cause mortality during ICU admission.

    Time frame: Up to ICU discharge or 28 days.

  2. Duration of Respiratory Support

    Duration of HFNC therapy and invasive mechanical ventilation among patients requiring intubation.

    Time frame: Up to 28 days.

  3. Association Between Metabolomic Profiles and Clinical Phenotypes

    Association between metabolomic biomarkers and clinical phenotypes according to sex, age, and etiology of acute hypoxemic respiratory failure.

    Time frame: Baseline, day 3, and day 5.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Masclans JR, Dot I, Perez-Teran P. High-Flow Nasal Cannulae. The Quest for the Holy Grail in the Critical Respiratory Patient? Arch Bronconeumol (Engl Ed). 2019 Jun;55(6):291-292. doi: 10.1016/j.arbres.2018.07.015. Epub 2018 Sep 6. No abstract available. English, Spanish. PubMed 30195925 ↗
  • Blot PL, Chousterman BG, Santafe M, Cartailler J, Pacheco A, Magret M, Masclans JR, Artigas A, Roca O, Garcia-de-Acilu M. Subphenotypes in patients with acute respiratory distress syndrome treated with high-flow oxygen. Crit Care. 2023 Nov 1;27(1):419. doi: 10.1186/s13054-023-04687-0. PubMed 37915062 ↗
  • Garcia-de-Acilu M, Marin-Corral J, Vazquez A, Ruano L, Magret M, Ferrer R, Masclans JR, Roca O. Hypoxemic Patients With Bilateral Infiltrates Treated With High-Flow Nasal Cannula Present a Similar Pattern of Biomarkers of Inflammation and Injury to Acute Respiratory Distress Syndrome Patients. Crit Care Med. 2017 Nov;45(11):1845-1853. doi: 10.1097/CCM.0000000000002647. PubMed 28806218 ↗
  • Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernandez G, Garcia-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376. doi: 10.1164/rccm.201803-0589OC. PubMed 30576221 ↗
  • Manrique S, Claverias L, Magret M, Masclans JR, Bodi M, Trefler S, Canadell L, Diaz E, Sole-Violan J, Bisbal-Andres E, Natera RG, Moreno AA, Vallverdu M, Ballesteros JC, Socias L, Vidal FG, Sancho S, Martin-Loeches I, Rodriguez A. Timing of intubation and ICU mortality in COVID-19 patients: a retrospective analysis of 4198 critically ill patients during the first and second waves. BMC Anesthesiol. 2023 Apr 27;23(1):140. doi: 10.1186/s12871-023-02081-5. PubMed 37106321 ↗
  • Molano-Franco D, Viruez-Soto A, Gomez M, Beltran E, Villabon M, Sosa A, Ortiz L, Orozco E, Hurtado A, Sanchez L, Arias-Reyes C, Soliz J, Masclans JR. Impact of High-Flow Nasal Cannula Use in Subjects With COVID-19 ARDS at High Altitudes: Clinical Presentation and Prognostic Factors. Respir Care. 2023 Dec 28;69(1):99-105. doi: 10.4187/respcare.10839. PubMed 37311630 ↗
  • Parrilla-Gomez FJ, Marin-Corral J, Castellvi-Font A, Perez-Teran P, Picazo L, Ravelo-Barba J, Campano-Garcia M, Festa O, Restrepo M, Masclans JR. Switches in non-invasive respiratory support strategies during acute hypoxemic respiratory failure: Need to monitoring from a retrospective observational study. Med Intensiva (Engl Ed). 2024 Apr;48(4):200-210. doi: 10.1016/j.medine.2023.11.006. Epub 2023 Nov 18. PubMed 37985338 ↗
  • Madrid-Gambin F, Oller S, Marco S, Pozo OJ, Andres-Lacueva C, Llorach R. Quantitative plasma profiling by 1H NMR-based metabolomics: impact of sample treatment. Front Mol Biosci. 2023 Jun 2;10:1125582. doi: 10.3389/fmolb.2023.1125582. eCollection 2023. PubMed 37333016 ↗
  • Gomez-Gomez A, Rodriguez-Morato J, Haro N, Marin-Corral J, Masclans JR, Pozo OJ. Untargeted detection of the carbonyl metabolome by chemical derivatization and liquid chromatography-tandem mass spectrometry in precursor ion scan mode: Elucidation of COVID-19 severity biomarkers. Anal Chim Acta. 2022 Mar 1;1196:339405. doi: 10.1016/j.aca.2021.339405. Epub 2022 Jan 4. PubMed 35151400 ↗

Individual participant data

Plan to share: Undecided — Both male and female participants will be included. Sex-specific metabolomic analyses will be explored as part of the study objectives.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 35 months is above that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
May 26, 2026
StartActual
Jun 4, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07607080
Lead sponsor
Hospital del Mar Research Institute (IMIM)
Collaborators
Instituto de Salud Carlos III, Fundació La Marató de TV3, Hospital Universitari de Bellvitge, Hospital Universitari Joan XXIII de Tarragona., Parc Taulí Hospital Universitari, Institute for Bioengineering of Catalonia
Responsible party
Andrea Castellvi (MD, Hospital del Mar Research Institute (IMIM)) — Principal investigator
First posted
May 26, 2026
Start date
Jun 4, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jun 8, 2026

Study contacts

Francisco José Parrilla-Gómez, MD, Phd
Contact
fparilla@hmar.cat
+34 747424848
Joan Ramon Masclans Enviz, MD, PhD
Contact
jrmasclans@hmar.cat
+34 639383309
Francisco José Parrilla-Gómez, MD, Phd
principal investigator · Hospital del Mar

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion